4.6 Review

Iron deficiency and cardiovascular disease

期刊

NATURE REVIEWS CARDIOLOGY
卷 12, 期 11, 页码 659-669

出版社

NATURE PORTFOLIO
DOI: 10.1038/nrcardio.2015.109

关键词

-

资金

  1. Amgen
  2. Sorin
  3. Vifor Pharma
  4. Bayer
  5. BRAHMS
  6. Novartis
  7. Keryx
  8. Abbott Vascular

向作者/读者索取更多资源

Iron deficiency affects up to one-third of the world's population, and is particularly common in elderly individuals and those with certain chronic diseases. Iron excess can be detrimental in cardiovascular illness, and research has now also brought anaemia and iron deficiency into the focus of cardiovascular medicine. Data indicate that iron deficiency has detrimental effects in patients with coronary artery disease, heart failure (HF), and pulmonary hypertension, and possibly in patients undergoing cardiac surgery. Around one-third of all patients with HF, and more than one-half of patients with pulmonary hypertension, are affected by iron deficiency. Patients with HF and iron deficiency have shown symptomatic improvements from intravenous iron administration, and some evidence suggests that these improvements occur irrespective of the presence of anaemia. Improved exercise capacity has been demonstrated after iron administration in patients with pulmonary hypertension. However, to avoid iron overload and T-cell activation, it seems that recipients of cardiac transplantations should not be treated with intravenous iron preparations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据